efficacy of semaglutide and safety once-weekly monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial sustain 6 trial Media Centre | EASD

In addition to this, there are some medical conditions like pernicious anemia or gastrointestinal disorders, where malabsorption is the main problem

What to Do About Breakouts While Taking GLP-1 Rossi said that if he had a patient present with acne while taking a GLP-1 drug, he would take a deeper dive into their hormone profile to see if there are any obvious imbalances

Then, wash your hands thoroughly with soap and remove the pen cap

The therapy lasted for 2 weeks

Generally, tirzepatide seems to have an edge over semaglutide, with people losing up to 22.5% of their weight, compared to an average of 17% with semaglutide